Found 61 articles for: "Atopic Dermatitis"
Cicatricial Ectropion in the Setting of IL-13 Inhibition
October 2026 | Volume 25 | Issue 10 | Case Reports | 971 | Copyright © October 2026
Introduction: Interleukin (IL)-13 is a key mediator of type 2 inflammation and an important therapeutic target in atopic dermatitis (AD). Although IL-4/IL-13 and IL-13 inhibitors...
Read MoreNordic European Countries Atopic Dermatitis (NECAD) I: Importance of Concordance With Skincare for Atopic Dermatitis
October 2026 | Volume 25 | Issue 10 | Original Article | 949 | Copyright © October 2026
Background: Atopic dermatitis (AD) is a chronic disease with a dysfunctional skin barrier, requiring continuous management to reduce symptoms and prevent flares. Topical treatmen...
Read MoreSAIGE III: The Role of Environmental Factors in the Development and Severity of Atopic Dermatitis in Young Children
October 2026 | Volume 25 | Issue 10 | Original Article | 935 | Copyright © October 2026
Background: Atopic dermatitis (AD) often manifests in infancy or early childhood, with significant impacts on quality of life and potential persistence into adulthood. Environmen...
Read MoreOff-Label Uses of Nemolizumab: A Narrative Review
October 2026 | Volume 25 | Issue 10 | Original Article | 956 | Copyright © October 2026
Background: Nemolizumab, a humanized monoclonal antibody targeting interleukin-31 receptor α (IL-31Rα), is approved for atopic dermatitis (AD) and prurigo nodularis (...
Read MoreThe Essential Role of Topical Targeted Therapy in Atopic Dermatitis
October 2026 | Volume 25 | Issue 10 | Original Article | 898 | Copyright © October 2026
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder marked by immune dysregulation, epidermal barrier dysfunction, microbiome imbalance, pruritus, and xero...
Read MorePost-Inflammatory Hyperpigmentation in Skin of Color Patients With Atopic Dermatitis
October 2026 | Volume 25 | Issue 10 | Features | 975 | Copyright © October 2026
Differences in Atopic Dermatitis Comorbidity and Treatment Patterns by Race
October 2026 | Volume 25 | Issue 10 | Editorials | 978 | Copyright © October 2026
Dual Therapy for Atopic Dermatitis: Lebrikizumab and JAK inhibitors used in Tandem for Treatment-Resistant Cases
June 2026 | Volume 25 | Issue 6 | Features | 569 | Copyright © June 2026
Treatment or Trigger? The Use of Biologic Therapy for Alopecia Areata
May 2026 | Volume 25 | Issue 5 | Features | 489 | Copyright © May 2026
Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel
March 2026 | Volume 25 | Issue 3 | Original Article | 221 | Copyright © March 2026
Background: Advanced topical nonsteroidal therapies are expanding options for atopic dermatitis (AD) by providing targeted anti-inflammatory control without many limitations of l...
Read MoreFrom Bald to Bold: Reversal of Alopecia Totalis in an Adolescent Using Dupilumab Monotherapy
March 2026 | Volume 25 | Issue 3 | Case Reports | 273 | Copyright © March 2026
Introduction: Alopecia areata (AA) is an autoimmune condition marked by non-scarring, patchy hair loss of the scalp which progresses in <10% of cases to alopecia totalis (AT),...
Read MoreRacial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United States
January 2026 | Volume 25 | Issue 1 | Original Article | 54 | Copyright © January 2026
Background: Atopic dermatitis (AD) disproportionately affects diverse patient populations, and complex factors influence access to treatment among different racial and ethnic gro...
Read MoreSAIGE I: Staphylococcus aureus, Immunological, Genetic, and Environmental (SAIGE) Factors Contributing to Atopic Dermatitis and the Use of Ceramide-Containing Skincare
October 2025 | Volume 24 | Issue 10 | Original Article | 1012 | Copyright © October 2025
Background: Atopic dermatitis (AD) is a common heterogeneous disorder that typically starts in infancy and early childhood, is associated with the development of comorbidities, a...
Read MoreSkin Barrier Benefits of a Natural Moisturizing Factor and Lipids-Based Moisturizer for Clinically Sensitive Skin
October 2025 | Volume 24 | Issue 10 | Original Article | 1029 | Copyright © October 2025
Read MoreEvaluating Topical Nitric Oxide Formulations Against an Atopic Dermatitis Methicillin-Resistant S. Aureus Isolate in a Porcine Infection Model
October 2025 | Volume 24 | Issue 10 | Original Article | 1003 | Copyright © October 2025
Background: Atopic dermatitis (AD) is a skin disorder characterized by reduced skin barrier function, which often leads to recurring infections, predominantly by Staphylococcus a...
Read More1% Colloidal Oatmeal Cream/Baby Wash Regimen Improved Atopic Dermatitis in Pediatric Patients From First Use
October 2025 | Volume 24 | Issue 10 | Original Article | 979 | Copyright © October 2025
Background and Objective: Atopic dermatitis (AD) affects 15% to 20% of children. Evidence supporting the effectiveness of colloidal oatmeal-based moisturizers in improving mild-t...
Read MoreRuxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | Original Article | 1036 | Copyright © October 2025
Atopic dermatitis (AD), a chronic inflammatory skin disease, is typically treated with topical corticosteroids in patients with mild to moderate disease, creating an ongoing need for nonsteroidal...
Read MoreUnderstanding Topical Steroid Withdrawal: Where Are We Now?
October 2025 | Volume 24 | Issue 10 | Features | 1057 | Copyright © October 2025
Beyond Inflammation and Itch: A Call for a Broader Framework in Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | Editorials | e62 | Copyright © October 2025
The Prevalence of Dupilumab-Associated Adverse Events Among Black and African American Adult Patients With Atopic Dermatitis: A Retrospective Chart Review
October 2025 | Volume 24 | Issue 10 | Features | 1054 | Copyright © October 2025
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
